Genentech to present new and encouraging long-term follow-up data across broad hematology portfolio at ash 2024

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th american society of hematology (ash) annual meeting and exposition, held december 7-10, 2024 in san diego, california. the data underscore genentech's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines polivy® (polatuzumab vedotin-pii.
ASH Ratings Summary
ASH Quant Ranking